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Table 1 Reaction setup.
FAS e 670A/G
lmVolume ebased
FAS e 1377 G/A
lmVolume ebased
1 1 Genomic DNA(100ng)
0.4 0.4 dNTP(0.2mm)
2 2 PCR buffer(10x)
0.6 0.6 MgCl2 (25mm)
0.8 0.8 Reverse Primer( 10pmol)
0.8 0.8 Forward Primer( 10pmol)
1 1 Taq DNA polymerase(5 U/mL)
13.4 13.4 Deionised H2O
20 20 Total
Fig. 1. Restriction digestion analysis of PCR products with and on 17% acryl-
amid gel. A: FAS-1377G/A Lane1: AA homozygote with 122 bp; Lane 2, 3:
GG homozygote with 104 bp; Lane 4, 5: GA heterozygote genotype with
122 bp and 104 bp .Size marker of DNA (50 bp ladder). B: FAS-670 A/G
Lane1: AG heterozygote genotype with 193 bp and 136 bp, Lane 2: 136 bp
GG homozygote and lane 3, 4:193 bp AA homozygote respectively; Size
marker of DNA (100 bp ladder).
Table 2 Thermocycling conditions for PCR.
1377- 670-
Temperature (C) Time Temperature (C) Time
Initial denaturation
for 1 cycle
94 2 min 94 2 min
Denaturation 94 30 s 94 30 s
Annealing 69 30 s 62 30 s
Extension 72 45 s 72 45 s
Go to step 2 for
35 cycles
Final extension 72 min 7 72 min 7
15Abstracts - 1st International Nastaran Cancer Symposium-2015 / Journal of Cellular Immunotherapy 1 (2015) 1e45In summary, our results indicate that the generated pool is
enriched of aptamer candidates for HER2 overexpressing cell line.
These results also suggest that cell ELABA can be confidently used
as an alternative method over flow cytometry to monitor SELEX
progress.
Keywords: Aptamer, Breast cancer, Cell enzyme-linked aptamer
based assay, Cell ELABA, Cell SELEX, HER2, Cell ELISA
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Extended Abstract
Introduction: There are more than 18 sub-types of breast cancer.-
This type of cancer is the second cause of mortality in women. The
etiology of breast cancer is multi factorial. Genetic factors are
involved in the etiology of breast cancer. The FAS gene has a critical
role in tumor growth and metastasis. Two polymorphisms have been
identified in the FAS promoter region in the silencer region, G to A
substitution at nucleotide position 1377 (rs2234767), and the other
in the enhancer region, A to G substitution at nucleotide position
670 (rs1800682). These polymorphisms have been shown to change
the transcription activities of FAS gene. In the present study, we
aimed to determine the linkage disequilibrium between -670 A>G
and -1377 G>A polymorphisms in FAS gene in patients with breast
cancer and controls.
Materials and methods: We carried out a case-control genetic
study in a population selected from Omid Cancer Hospital of Mash-
had in north - eastern part of Iran during the period from February
2013 - October 2014. This study involved a group of 115 female
patients with histologically-confirmed breast cancer and 115 healthy
controls with negative medical history. DNA was extracted by DNA
extraction kit. Spectrophotometry and 1% agarose gel electrophoresis
methods were used to determine quality of the extracted DNA. The
primer sequences were as follows:
FAS -1377 G/A: F 50-TGTGTGCACAAGGCTGGCGC -30
FAS -1377 G/A: R 50-TGCATCTGTCACTGCACTTACCACCA- 3
FAS -670 A/G: F 50- ATAGCTGGGGCTATGCGATT-30
FAS -670 A/G: R 50-CATTTGACTGGGCTGTCCAT-30
These target sequences were amplified according to the recipe in
Table1. PCR amplifications were conducted in Personal Cycler™
amplificator (Biometra, Germany). Thermal cycling conditions are
shown in Table 2. 4 mL of PCR products were digested overnight
at 37C in a 10 mL reaction volume containing 1 units of BstuI and
ScrfI (Fermentas, Germany) were recruited as endonuclease enzymesto detect -1377G/A and -670A/G gene polymorphisms, respectively.
After overnight digestion, solutions were analyzed on 17% acryla-
mide gel and then visualized with silver-nitrate staining (Fig. 1).
Statistical analysis: The statistical analysis of the data was per-
formed by using the SPSS 18.0 software. Genotypes and alleles
were compared between groups by use of c2 test. The strength of
the association between the polymorphisms and cancer risk was
measured by odds ratios (ORs) with 95% confidence intervals
(CIs). The allele frequencies of 2 polymorphisms in case and control
groups followed Hardy-Weinberg’s law of Equilibrium (P > 0.05).
Result: The frequencies of the two alleles in breast cancer patients
were compared with the frequencies in the healthy control subjects. In
the same order , GG, GA and AA genotype frequencies for FAS -1377
polymorphism in patients were 30.4%, 49.6% and 20%, whereas in
control groups were 26.1%, 50.4% and 23.5%, and there was no sig-
nificant difference between case and control groups. Furthermore,
genotype frequencies of FAS -670 AA, AG and GG in patients
were 52.2%, 39.1% and 8.7% respectively. The result of genotype fre-
quencies in control groups for FAS -670 AA, AG and GG were 47%,
16 Abstracts - 1st International Nastaran Cancer Symposium-2015 / Journal of Cellular Immunotherapy 1 (2015) 1e4541% and 10.4%, which Showed insignificant difference as compared
with patients genotypes .These results showed that FAS1377G/A
and FAS -670 A/G gene polymorphisms had a strong linkage disequi-
librium with ( p value <0.001).
Discussion: Several polymorphism sites have been identified to
influence the development of breast cancer. Death receptor activation
triggers extrinsic apoptotic pathways, which in some cell types may
be enough to carry apoptosis. Several previous researches concen-
trated on the association between different gene polymorphisms
within cell death pathways and the risk of developing malignancies
and developing cancers. FAS polymorphisms may play different, con-
text-dependent roles in cancer Crew et al., found no association
between breast cancer and FAS -1377 G/A, FAS-670 G/A polymor-
phisms. On the other hand, Zhang et al., reported an important asso-
ciation between FAS 1377G/A gene polymorphism and risk of breast
cancer, but they reported no association between FAS -670 G/A and
breast cancer risk.
Hashemi et al., mentioned that the FAS-1377 G/A did not affect
the risk of breast cancer, while FAS -670 G/A gene polymorphism
was risk factor. Krippl et al., in a study of 500 breast cancer
patients and 500 controls in a Caucasian population in Austria,
found a significant association between FAS-1377G/A and
increased risk of breast cancer, but they reported no associations
with FAS -670G/ A.
Our study indicates the lack of association between
FAS1377G>A and FAS -670 A/G gene polymorphisms and risk
of breast cancer. Also, a main linkage disequilibrium is found
betweenFAS1377G/A and FAS -670 A/G gene polymorphisms in
case and control groups.
One of the limitation in our study is small sample size.
While there have been current discussions on the influence of var-
ious polymorphisms within the signaling molecules relevant to cell
death pathways, and cancer formation, this work has proved its worth.
Also, we suggest to study the other candidate gene polymorphism
which may be beneficial for identifying the factors involved in breast
cancer.
Keywords: Breast cancer, FAS1377G>A, FAS -670 A/G, Link-
age disequilibrium, Gene polymorphism
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Extended Abstract
Introduction: Cisplatin is widely used for the treatment of
many malignancies. The activity of cisplatin is thought to be a
result of formation of inter- and intra-strand DNA crosslinks. How-
ever, the events leading to apoptotic cell death after cisplatin treat-
ment are not well understood and may involve regulation of the
expression of multiple genes. BCL2 family represents major regu-
lators of apoptosis. The balance of cell death protectors and
inducers in the BCL2 family of proteins has been proposed as acommon determinant of the susceptibility of cells to apoptotic
cell death induced by various stimuli. In the present study, we com-
pared the anticancer potential of cisplatin on the MCF-7 and T47D
breast cancer cell lines. The effect of cisplatin on tumor cell apop-
tosis induction as well as on BCL2L12, BAX and BAD expression
was studied.
Materials and methods: Cell culture and drug treatment:
MCF-7 and T47D cells were maintained in RPMI 1640 supplemented
with 10% fetal bovine serum, 2 mM glutamine and 1% penicillin e
streptomycin under standard culture conditions. Cells were treated
with different concentrations of cisplatin for 24 h.
Cytotoxicity assay: The cytotoxicity of cisplatin was assessed by
the MTT assay. Cells were seeded on 96-well micro plates at a density
of 1104 cells per well in 100 ml of RPMI 1640 medium. After incu-
bation at 37C in a humidified incubator for 24 h, cells were exposed
to various concentrations of cisplatin for 24 h. After incubation, 10 ml
of MTT solution (5 mg/ml in PBS) was added to the cells. Cells were
incubated at 37C for 3 h and the optical density was measured using
a microplate reader at 540 nm.
RNA extraction and cDNA synthesis: Total RNA was isolated
from cells using RNX-Plus Solution (CinaGen, IRAN). RNA sam-
ples with the A260/A230 and A260/A280 ratios above 1.7 were
selected for cDNA synthesis. cDNA synthesis was performed
using Revert AidTMFirst Strand cDNA Synthesis Kit (Fermentas,
USA).
Primer design: Primers were designed using primer express soft-
ware v.3.0 (Applied Biosystems, USA). Synthesis of these primers
was performed by Bioneer, South Korea.
Real-time RT-PCR: Power SYBR Green PCR Master Mix
(Applied Biosystems, Warrington, UK) was employed to perform
quantitative PCR on the Rotor-Gene 6000 (Corbett Research, Aus-
tralia) applying the following thermal-cycling conditions: 10min at
95C (1 repeat) as first denaturation and Hot-start enzyme activation,
followed by 40 cycles at 95C for 15s and 60C for 1 min. Each com-
plete amplification stage was followed by a melting stage; at 95C for
15s, 60C for 30s and 95C for 15s. The PCR amplification was per-
formed in 20 ml reaction containing 10 ml Power SYBR Green PCR
Master Mix (2x), 0.6 ml Forward primer (0.4mM), 0.6 ml Reverse pri-
mer (0.4 mM), 5ml first-strand cDNA (100 ng) and 3.8 ml double-dis-
tillated water. Calculation of the gene expression was carried out
using comparative threshold cycle. The mean threshold cycle was
obtained from triplicate amplifications during the exponential phase.
Then target /control gene expression ratios were calculated by 2 -DDCt
formula.
Statistical analysis: The P-value of <0.05 was considered statisti-
cally significant for student's t-test analysis.
Result: In vitro toxicity and IC50 determination: The in vitro
anticancer cytotoxic activity of cisplatin on MCF-7 and T47D cells,
expressed as % cell viability, is shown in Fig. 1. The IC50 of cisplatin,
for MCF-7 and T47D cell lines were calculated to be 47.672mM and
43.694 mM, respectively.
BCL2L12, BAX, BAD mRNA expression after cisplatin
exposure: Alterations in gene expression were evaluated in
MCF-7 and T47D cells treated with 47.672 mM and 43.694 mM
of cisplatin, respectively. Treatment of MCF-7 cells with cisplatin,
resulted in the up regulation of the BAX mRNA levels. However,
we found no significant change in BCL2L12 and BAD mRNA
expression levels. In the case of T47D cells treated by cisplatin,
we observed up regulation of the BAX and BCL2L12 mRNA lev-
els. However we found no significant change in the BAD mRNA
levels.
